Pyrrolidine GR Modulators for Anti-Inflammatory Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic glucocorticoid (GC) treatment for inflammatory diseases is hampered by severe adverse effects, and existing partial agonists or selective glucocorticoid receptor modulators have not been approved for clinical use, necessitating the development of novel compounds that effectively modulate the glucocorticoid receptor to reduce inflammation while minimizing side effects.
Innovation Solution
Development of novel compounds according to general formula (I) that act as potent modulators of the glucocorticoid receptor, potentially reducing inflammation while minimizing adverse effects by selectively modulating the receptor's transactivation and transrepression pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chronic glucocorticoid treatment is used to treat inflammatory diseases, then anti-inflammatory and immunosuppressive effects are achieved, but severe adverse effects occur including insulin resistance, diabetes, hypertension, glaucoma, depression, osteoporosis, and adrenal suppression
Solution Approach 1:
The patent applies local quality by designing compounds that selectively modulate different functions of the glucocorticoid receptor. The compounds favor transrepression pathways (anti-inflammatory effects) over transactivation pathways (adverse effects), creating a localized functional bias in receptor signaling to achieve therapeutic benefits while minimizing harmful side effects
Solution Approach 2:
The patent changes the pharmacological parameters of glucocorticoid receptor modulation by introducing novel compounds with specific molecular structures (formula I) that alter the receptor's conformational state. This changes the balance between transactivation and transrepression, shifting the therapeutic profile to reduce adverse effects while maintaining anti-inflammatory activity
2Object-affected harmful factors
If gradual glucocorticoid tapering is used to reduce withdrawal symptoms, then adrenal suppression is managed, but treatment duration is extended and relapse risk increases
Solution Approach 1:
The patent develops novel compounds that provide potent and sustained glucocorticoid receptor modulation with a more favorable pharmacokinetic profile. These compounds aim to replace the need for prolonged gradual tapering with a shorter, more effective treatment course that maintains therapeutic levels without causing severe withdrawal symptoms upon discontinuation
3Object-affected harmful factors
If partial agonists or selective glucocorticoid receptor modulators are developed to reduce adverse effects, then transactivation pathways are avoided, but none have been approved for clinical use yet
Solution Approach 1:
The patent creates composite molecular structures combining specific pharmacophores (formula I) that integrate multiple functional elements: glucocorticoid receptor binding capability, selective transrepression activation, and reduced transactivation stimulation. This composite molecular design aims to achieve the therapeutic profile needed for clinical approval by balancing efficacy and safety
Data Source
AI summary
The invention relates to compounds according to general formula (I)which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.